Enzalutamide Use in Patients With mHSPC Who Received Prior Local Therapy

Neal Shore, MD, FACS, the US chief medical officer of Surgery and Oncology at GenesisCare and the director and certified principal investigator at the Carolina Urologic Research Center, discusses the purpose behind investigating enzalutamide in a cohort of patients with metastatic hormone-sensitive prostate cancer who were previously treated with local therapy as a post-hoc analysis of the ARCHES study (NCT02677896).

According to Shore, the primary analysis of the ARCHES study showed positive results for the primary end point of radiographic progression-free survival and the secondary end point of overall survival. The next important thing to research was how the prior local therapy subgroup performed on enzalutamide treatment compared with androgen deprivation therapy (ADT).

Results showed that prior local therapy subgroup had longer survival benefit with enzalutamide compared with ADT.

Transcription:

0:07 | After we met the primary end point of rPFS, a secondary end point of overall survival [OS] was also very nicely met and previously published and demonstrated. For the analysis presented at AUA, we looked at a subset analysis of the patients who would have had prior radical prostatectomy or radiation to the primary or even both. What we found in that population, many would fall under the category of oligoprogressive disease, or they may have had a high-volume progressive disease. Additionally, patients with mHSPC also did exceptionally well with the combination of ADT and enzalutamide vs conventional monotherapy ADT.

1:04 | And, I think this is important for urology, radiation oncology, and medical oncology colleagues to recognize the absolute importance of combination therapy now for the mHSPC population of ADT and enzalutamide, and not to hold on to the traditional monotherapy ADT. That’s what our data demonstrated in this subpopulation.